Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08089-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Linjie Bian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Prostatic Neoplasms, Oligopeptides. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Nuclear Technology R&D Program, Shanghai Collaborative Innovation Project, the Key Program of the National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: To evaluate lesion detection patterns and the risk-stratification value of paired 68Ga-PSMA-11 and 18F-FDG PET/CT in patients with post-prostatectomy biochemical recurrence (BCR) and negative conventional imaging, and to explore the hypothesis-generating biological context of dual-tracer phenotypes using public single-cell transcriptomic data. METHODS: This retrospective single-center study included patients with post-prostatectomy BCR who underwent paired 68Ga-PSMA-11 and 18F-FDG PET/CT within 14 days and had negative conventional imaging within 1 month before PET/CT. Overall dual-tracer PET positivity was defined as at least 1 positive lesion on either tracer. Among patients with PET-detectable disease on either tracer, phenotypes were classified as PSMA+/FDG-, PSMA+/FDG+, or PSMA-/FDG+. Public single-cell RNA sequencing data were analyzed to assess the relationship between FOLH1 expression and glycolytic activity. RESULTS: Among 58 included patients, 21 (36.2%) had at least one positive lesion on either tracer. Overall dual-tracer PET positivity increased across PSA strata and with a greater number of prespecified risk features (both P for trend < 0.001). Older age and higher PSA at PET were independently associated with overall dual-tracer PET positivity. Among patients with PET-detectable disease on either tracer, FDG-avid disease was associated with pathologic stage ≥pT3, pathologic N1 disease, recurrence within 3 years after radical prostatectomy, and PSA doubling time ≤ 6 months. In the public single-cell cohort, FOLH1 expression and glycolytic activity showed only a weak association. CONCLUSION: Paired 68Ga-PSMA-11 and 18F-FDG PET/CT revealed heterogeneity beyond lesion detection in patients with post-prostatectomy BCR and negative conventional imaging. Among patients with PET-detectable disease on either tracer, FDG-avid disease was enriched for adverse clinicopathologic features, and public single-cell transcriptomic analysis provided hypothesis-generating biological context for divergent dual-tracer phenotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
- Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai, 200032, China. shaoli-song@163.com.
Förderung
- Nuclear Technology R&D Program
- Shanghai Collaborative Innovation Project
- the Key Program of the National Natural Science Foundation of China
- the Shanghai Municipal Science and Technology Commission
Zitieren
APA
Bian, L., Huang, X., Zhu, B., Liu, C., Xu, X., Hu, S., & Song, S. (2026). Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08089-6
Vancouver
Bian L, Huang X, Zhu B, Liu C, Xu X, Hu S, et al. Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08089-6
BibTeX
@article{Bian2026,
author = {Bian, Linjie and Huang, Xuan and Zhu, Bin and Liu, Chang and Xu, Xiaoping and Hu, Silong and Song, Shaoli},
title = {Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08089-6}
}
EUVIMED